News und Analysen
Acadia Healthcare Reports First Quarter 2023 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2023.
First Quarter Highlights
-
Revenue totaled $704.3 million, an
Chemed Reports First-Quarter 2023 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
Charles River Laboratories International, Inc. (NYSE: CRL) today launched Apollo™, an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study
Premier, Inc. Named One of the 2023 World’s Most Ethical Companies® by Ethisphere® for 16th Consecutive Year
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management
Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus
Premier Inc. to Participate in Barclays Global Healthcare Conference on March 14, 2023
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Barclays
Acadia Healthcare to Participate in March Investor Conferences
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two investor conferences in March.
On Tuesday, March 7, 2023, the Company will participate in
Chemed Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023, at approximately 1:20 p.m
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in
Acadia Healthcare Reports Fourth Quarter 2022 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2022.
Fourth Quarter Highlights
-
Revenue totaled $675.3
Chemed Reports Fourth-Quarter 2022 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Novocure is a global oncology company working to extend survival in some of
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors.
“We are honored to welcome Dr. Ocean to our board of directors,” said
Premier Inc. Acquires 100 Top Hospitals® Program
Premier Inc. (NASDAQ: PINC) acquired the 100 Top Hospitals® program from Merative (formerly IBM Watson Health). The program will be integrated within PINC AI™, Premier’s technology and services
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2022 and provided guidance for 2023. For the quarter, revenue was $1.10
Chemed Corporation Declares Quarterly Dividend of 38 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on March 17, 2023, to
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a